Cutaneous lupus erythematosus: Immunologic mechanisms and current therapeutic approaches

Cutaneous lupus erythematosus (CLE) is an autoimmune dermatologic condition that primarily a ects the skin, constantly associated with systemic lupus erythematosus (SLE). It's characterized by distinct skin lesions, including erythematous pillars, photosensitivity, and the hallmark butter y rash. The immunologic mechanisms bolstering CLE are complex, involving dysregulated vulnerable responses analogous as the product of autoantibodies (-dsDNA), abnormal activation of T- cells (particularly Th1 and Th17 cells), and type I interferon signaling. heritable factors, environmental triggers, and vulnerable system dysregulation play signi cant places in the pathogenesis of CLE. Current remedial approaches concentrate on topical corticosteroids, immunosuppressive agents like hydroxychloroquine, and birth antidotes analogous as belimumab. While these treatments o er symptom control, challenges remain, including treatment resistance and the need for personalized medicine. Advances in understanding the immunologic mechanisms of CLE are essential for developing further targeted antidotes. This review highlights the immunopathogenesis of CLE and examines the current remedial strategies, with an emphasis on the need for continued disquisition to meliorate treatment issues.